In an effort to address concerns regarding pharmaceutical manufacturers’ coupon and copayment programs and the resulting costs to federal government health programs, the National Council for Prescription Drug Programs’ (NCPDP) task group is pulling together clear guidance around the OIG guidelines. The task group is looking at a variety of …